Refractory, intensive care–dependent NMDAR encephalitis

This research study establishes a formal definition for refractory, intensive care–dependent NMDAR encephalitis (RI-NMDARE), identifying it as cases requiring over 90 days of ICU support despite second-line immunotherapy. The authors found that approximately 12% of severe patients fall into this high-risk category, which is characterized by a rapidly progressing disease and a higher prevalence of ovarian teratomas. Clinically, these patients often exhibit a specific triad of seizures, movement disorders, and dysautonomia, alongside elevated biological markers like CSF antibody titers and serum neurofilament levels. Despite receiving earlier and more aggressive treatments, individuals with this phenotype experience higher mortality rates and significantly poorer long-term recovery. The study suggests that early recognition of these clinical and biomarker profiles is vital for implementing targeted third-line therapies to improve outcomes. Ultimately, the findings highlight that treatment resistance may be driven by underlying immune mechanisms rather than delays in standard medical intervention.